Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Curr Genomics ; 21(6): 464-477, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33093808

ABSTRACT

BACKGROUND: In this review we survey medical treatments and research strategies, and we discuss why they have failed to cure degenerative disc diseases or even slow down the degenerative process. OBJECTIVE: We seek to stimulate discussion with respect to changing the medical paradigm associated with treatments and research applied to degenerative disc diseases. METHOD PROPOSAL: We summarize a Biological Transformation therapy for curing chronic inflammations and degenerative disc diseases, as was previously described in the book Biological Transformations controlled by the Mind Volume 1. PRELIMINARY STUDIES: A single-patient case study is presented that documents complete recovery from an advanced lumbar bilateral discopathy and long-term hypertrophic chronic rhinitis by application of the method proposed. CONCLUSION: Biological transformations controlled by the mind can be applied by men and women in order to improve their quality of life and cure degenerative disc diseases and chronic inflammations illnesses.

2.
CNS Neurol Disord Drug Targets ; 10(2): 149-62, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21222631

ABSTRACT

Age-related dementias such as Alzheimer disease (AD) have been linked to vascular disorders like hypertension, diabetes and atherosclerosis. These risk factors cause ischemia, inflammation, oxidative damage and consequently reperfusion, which is largely due to reactive oxygen species (ROS) that are believed to induce mitochondrial damage. At higher concentrations, ROS can cause cell injury and death which occurs during the aging process, where oxidative stress is incremented due to an accelerated generation of ROS and a gradual decline in cellular antioxidant defense mechanisms. Neuronal mitochondria are especially vulnerable to oxidative stress due to their role in energy supply and use, causing a cascade of debilitating factors such as the production of giant and/or vulnerable young mitochondrion who's DNA has been compromised. Therefore, mitochondria specific antioxidants such as acetyl-L-carnitine and R-alphalipoic acid seem to be potential treatments for AD. They target the factors that damage mitochondria and reverse its effect, thus eliminating the imbalance seen in energy production and amyloid beta oxidation and making these antioxidants very powerful alternate strategies for the treatment of AD.


Subject(s)
Alzheimer Disease/drug therapy , Amyloid beta-Peptides/metabolism , Antioxidants/therapeutic use , Mitochondria/metabolism , Aging , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Animals , Blood-Brain Barrier , Brain/blood supply , Brain/pathology , Cerebrovascular Disorders/physiopathology , Humans , Mice , Mitochondria/pathology
3.
Pharmaceuticals (Basel) ; 3(1): 158-187, 2010 Jan 19.
Article in English | MEDLINE | ID: mdl-27713247

ABSTRACT

Mitochondrial dysfunction may be a principal underlying event in aging, including age-associated brain degeneration. Mitochondria provide energy for basic metabolic processes. Their decay with age impairs cellular metabolism and leads to a decline of cellular function. Alzheimer disease (AD) and cerebrovascular accidents (CVAs) are two leading causes of age-related dementia. Increasing evidence strongly supports the theory that oxidative stress, largely due to reactive oxygen species (ROS), induces mitochondrial damage, which arises from chronic hypoperfusion and is primarily responsible for the pathogenesis that underlies both disease processes. Mitochondrial membrane potential, respiratory control ratios and cellular oxygen consumption decline with age and correlate with increased oxidant production. The sustained hypoperfusion and oxidative stress in brain tissues can stimulate the expression of nitric oxide synthases (NOSs) and brain endothelium probably increase the accumulation of oxidative stress products, which therefore contributes to blood brain barrier (BBB) breakdown and brain parenchymal cell damage. Determining the mechanisms behind these imbalances may provide crucial information in the development of new, more effective therapies for stroke and AD patients in the near future.

4.
Neurotox Res ; 16(3): 293-305, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19526276

ABSTRACT

Nitric oxide (NO) is an important regulatory molecule for the host defense that plays a fundamental role in the cardiovascular, immune, and nervous systems. NO is synthesized through the conversion of L-arginine to L-citrulline by the enzyme NO synthase (NOS), which is found in three isoforms classified as neuronal (nNOS), inducible (iNOS), and endothelial (eNOS). Recent evidence supports the theory that this bioactive molecule has an influential role in the disruption of normal brain and vascular homeostasis, a condition known to elucidate chronic hypoperfusion which ultimately causes the development of brain lesions and the pathology that typify Alzheimer disease (AD). In addition, vascular NO activity appears to be a major contributor to this pathology before any overexpression of NOS isoforms is observed in the neuron, glia, and microglia of the brain tree, where the overexpression the NOS isoforms causes the formation of a large amount of NO. We hypothesize that since an imbalance between the NOS isoforms and endothelin-1 (ET-1), a human gene that encodes for blood vessel constriction, can cause antioxidant system insufficiency; by using pharmacological intervention with NO donors and/or NO suppressors, the brain lesions and the downstream progression of brain pathology and dementia in AD should be delayed or minimized.


Subject(s)
Alzheimer Disease , Brain Injuries/etiology , Brain Injuries/metabolism , Nitric Oxide/metabolism , Alzheimer Disease/complications , Alzheimer Disease/etiology , Alzheimer Disease/metabolism , Animals , Brain/metabolism , Brain/pathology , Cardiovascular Diseases/physiopathology , Disease Progression , Endothelin-1/metabolism , Humans , Nitric Oxide Synthase/classification , Nitric Oxide Synthase/metabolism , Oxidative Stress , Protein Isoforms/metabolism
5.
Article in English | MEDLINE | ID: mdl-15751450

ABSTRACT

The purpose of this study was to evaluate the efficacy of an integrative treatment approach on cognitive performance. The study sample comprised 35 medically ill patients (20 male, 15 female) with an average age of 71.05, who were diagnosed with mild dementia and depression. These patients were evaluated at baseline and at six, 12, and 24 months of treatment, which included antidepressants (sertraline, citalopram, or venlafaxine XR, alone or in combination with bupropion XR), cholinesterase inhibitors (donepezil, rivastigmine or galantamine), as well as vitamins and supplements (multivitamins, vitamin E, alpha-lipoic acid, omega-3 and coenzyme Q-10). Patients were encouraged to modify their diet and lifestyle and perform mild physical exercises. Results show that the integrative treatment not only protracted cognitive decline for 24 months but even improved cognition, especially memory and frontal lobe functions.


Subject(s)
Alzheimer Disease/complications , Cognition Disorders/prevention & control , Depression/complications , Ubiquinone/analogs & derivatives , Aged , Alzheimer Disease/therapy , Antidepressive Agents/therapeutic use , Antioxidants/therapeutic use , Cholinesterase Inhibitors/therapeutic use , Coenzymes , Cognition Disorders/etiology , Combined Modality Therapy , Depression/therapy , Diet , Dietary Supplements , Exercise , Fatty Acids, Omega-3/therapeutic use , Female , Humans , Life Style , Male , Neuropsychological Tests , Treatment Outcome , Ubiquinone/therapeutic use , Vitamins/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL